Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence
Conditions
Uterine Cervical Cancer - Diffusion-weighted MRI - Recurrence
Conditions: official terms
Recurrence - Uterine Cervical Neoplasms - Uterine Neoplasms
Conditions: Keywords
Uterine cervical cancer, diffusion-weighted MRI, recurrence
Study Type
Interventional
Study Phase
N/A
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Intervention
Name: Diffusion weighted MRI (DW- MRI)
Type: Procedure
Overall Status
Recruiting
Summary
Uterine cervical cancer is the second most common female malignancy. Therapy monitoring is essential to detect early recurrence. Diffusion-weighted magnetic resonance imaging is an emerging MRI imaging technique which has a potential value for the detection of primary and recurrent disease and for the assessment of response to therapy. The purpose of this project is to evaluate the predictive value of DWI during and after therapy in the prediction of recurrence of cervical uterine cancer. It will be considered whether DWI is able to provide early information about the response to therapy. This could enable the identification of less- or non-responsive tumors and in this way therapy can be adapted as soon as possible. Hence the investigators could offer the patient a more efficient treatment scheme and a reduction in toxicity related to the treatment could be established.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Female
Criteria: Inclusion Criteria:

- Patients diagnosed with cervical uterine cancer are, on a voluntary basis, enrolled in the study. These are patients who either underwent curative chemoradiation (mainly patients with advanced stage cancer) or neoadjuvant chemotherapy (predominantly in patients with early stage cancer) before undergoing surgery.

Exclusion Criteria:

- Patients with known contra-indications for MRI (cardiac pacemakers, cochlear implants, claustrophobic patients) will be excluded from this study. And so are patients with contra-indications to Gadolinium-based contrast agents and patients with a known restricted renal function (GFR < 30 ml/min).
Location
University Hospital Gasthuisberg
Leuven, Belgium
Status: Recruiting
Start Date
November 2010
Completion Date
April 2016
Sponsors
Universitaire Ziekenhuizen Leuven
Source
Universitaire Ziekenhuizen Leuven
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page